Harapan: Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT02396979
Collaborator
University of Malaya (Other), National Institute on Drug Abuse (NIDA) (NIH)
300
4
59

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the relative impact a medical drug (methadone) or behavioral counseling program (Holistic Health Recovery Program) or both (methadone and Holistic Health Recovery Program) has on reducing HIV-related risk behaviors and illicit drug use among opioid-dependent, HIV-infected individuals in prison when given 90 to 180 days prior to leaving prison.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia
Study Start Date :
Jan 1, 2010
Actual Primary Completion Date :
Dec 1, 2014
Actual Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Methadone Maintenance

Methadone induction and management provided

Drug: Methadone

Experimental: Holistic Health Recovery Program

Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.

Behavioral: Holistic Health Recovery Program

Experimental: Methadone Maintenance and Holistic Health Recovery Prorgram

Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).

Drug: Methadone

Behavioral: Holistic Health Recovery Program

No Intervention: Standard of Care

Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.

Outcome Measures

Primary Outcome Measures

  1. HIV Risk Events [Change from Baseline in HIV Risk Events at Months 3, 6, 9 and 12]

    The primary outcome is the number of HIV high risk events. This outcome will be constructed from a composite measure counting the number of unprotected vaginal and anal insertive events and needle-or-syringe-sharing events with an HIV- or HIV-status-unknown partner that might result in HIV transmission to an uninfected partner. As such, the primary outcome will be the number of high-risk events during the period of observation in the intervention. All data will be self-reported by the participant.

Secondary Outcome Measures

  1. HIV Quality of Life [Change from Baseline in HIV Quality of Life at Months 3, 6, 9 and 12]

    This outcome will be measured by a series of questions that will be used to produce a composite score that will indicate the participant's overall quality of life as it relates to their HIV status. These questions will ask about your general health and your ability to perform daily activities in your life. All data will be self-reported by the participant.

  2. Relapse to Drug Use [Change from Baseline in Relapse to Drug Use at Months 3, 6, 9 and 12]

    This outcome will be measured as any opioid drug use after release from prison. This outcome will be measured in two ways. First, participants will provide a monthly urine sample that will be tested for the presence of opioids. Second, participants will answer questions about their drug use since the time of their last interview.

  3. Addiction Severity [Change from Baseline in Addiction Severity at Months 3, 6, 9 and 12]

    This outcome will be measured by a series of questions about the participant's drug use. These questions will be used to produce a composite score which indicates the severity of the participant's addiction.

  4. Reincarceration [Any reincarceration to prison during the 12 month post-release follow-up period]

    This outcome will be measured by both self-report and objective data from the Malaysian Ministry of Prisons. Self-report questions will be used to ask participants if they have been arrested by police (placed in jail) or incarcerated in prison during the time since the last interview. Objective data will also be obtained from the Ministry of Prisons which will indicate if the participant has been reincarcerated in one of Malaysia's prison during the 12 months since they were initially released from prison.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • HIV-infected

  • Clinical Diagnosis of Opioid Dependence

  • Fluent in Bahasa Malaysia or English

  • Within 90 to 180 days of release from prison

  • Planning to live in Klang Valley region after release from prison

  • Able to provide informed consent

Exclusion Criteria:
  • Pregnancy or planning to become pregnant (female only)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yale University
  • University of Malaya
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Frederick L Altice, M.D., Yale University
  • Principal Investigator: Adeeba Kamarulzaman, M.D., University of Malaya

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT02396979
Other Study ID Numbers:
  • 0908005646
  • R01DA025943
First Posted:
Mar 24, 2015
Last Update Posted:
Jan 17, 2018
Last Verified:
Jan 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 17, 2018